Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 negative
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
PD-L1 elevation (15)
TMB-H + PD-L1 expression (15)
EGFR mutation + PD-L1 overexpression (8)
TMB-H + PD-L1 overexpression (7)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + PD-L1 expression (5)
KRAS G12C + PD-L1 overexpression (4)
KRAS mutation + PD-L1 expression (4)
MSI-H/dMMR + PD-L1 expression (4)
PD-L1 expression + EGFR mutation (4)
CD74-ROS1 F2004L + PD-L1 expression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MSI-H/dMMR + TMB-H + PD-L1 negative (3)
PD-L1 expression + TMB-H (3)
PD-L1 overexpression + KRAS mutation (3)
ALK rearrangement + PD-L1 overepxression (2)
BRAF V600E + PD-L1 expression (2)
BRAF V600E + PD-L1 expression (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR exon 19 deletion + PD-L1 expression (2)
HER-2 amplification + PD-L1 expression (2)
KRAS G12C + PD-L1 underexpression (2)
KRAS mutation + PD-L1 negative (2)
MSI-H/dMMR + TMB-H + PD-L1 overexpression (2)
PD-1-L + PD-L1 elevation (2)
PD-L1 expression + NRAS Q61R + BRAF D594N (2)
PD-L1 expression + TMB-H + FANCA deletion (2)
PD-L1 overexpression + BRAF V600E (2)
PD-L1 overexpression + EGFR mutation (2)
PD-L1 overexpression + FGFR3 amplification (2)
PD-L1 overexpression + MET exon 14 mutation (2)
RAD51B promoter methylation + PD-L1 expression (2)
TMB-H + PD-L1 negative (2)
TMB-H + PD-L1 underexpression (2)
TMB-L + PD-L1 expression (2)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BAP1 R300Gfs*6 + PD-L1 expression (1)
BAP1 deletion + TMB-L + PD-L1 expression (1)
BRAF E501Q + PD-L1 negative (1)
BRAF V600 + LDH elevation + PD-L1 negative (1)
BRAF mutation + PD-L1 overexpression (1)
BRCA1 mutation + PD-L1 expression (1)
CDKN2A mutation + PD-L1 overexpression (1)
Chr del(9p) + PD-L1 overexpression (1)
DDR + PD-L1 expression (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
FGFR mutation + PD-L1 expression (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HLA-A*02 + PD-L1 expression (1)
HLA-A*02:01 + PD-L1 expression (1)
HRAS Q61R + TP53 P278S + PD-L1 overexpression (1)
KEAP1 mutation + TMB-H + PD-L1 overexpression (1)
KMT2C mutation + BCOR mutation + KDM5C mutation + PD-L1 expression (1)
KRAS G12C + PD-L1 expression (1)
KRAS G12C + PD-L1 underexpression + STK11 mutation (1)
KRAS mutation + PTPN11 overexpression + PD-L1 overexpression (1)
KRAS mutation + PD-L1 underexpression (1)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression (1)
LDHA-L + PD-L1 expression (1)
LDHB-L + PD-L1 expression (1)
MET exon 14 mutation + MET amplification + PD-L1 overexpression (1)
MGAM mutation + PD-L1 overexpression (1)
PAPPA2 mutation + PD-L1 expression (1)
PD-L1 amplification + CD3D overexpression (1)
PD-L1 amplification + HLA-DRA overexpression (1)
PD-L1 amplification + LAG3 overexpression (1)
PD-L1 amplification + PD-L2 amplification + TMB-H (1)
PD-L1 deletion + STK11 mutation (1)
PD-L1 elevation + CXCL10 elevation + TNFA elevation (1)
PD-L1 expression + BRAF negative (1)
PD-L1 expression + JAK2 mutation (1)
PD-L1 expression + KMT2D mutation (1)
PD-L1 expression + MSI-H/dMMR (1)
PD-L1 expression + MSI-L/dMMR (1)
PD-L1 expression + PIK3CA mutation (1)
PD-L1 expression + STK11 mutation (1)
PD-L1 expression + STK11 mutation + JAK2 mutation (1)
PD-L1 expression + T-cell gene signature (1)
PD-L1 negative + KRAS G12C (1)
PD-L1 negative + TMB-L (1)
PD-L1 negative + TMB-L + STING overexpression (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PD-L1 overexpression + KRAS G12C + TP53 mutation (1)
PD-L1 overexpression + RET-CCDC6 fusion (1)
PD-L1 overexpression + RET-KIF5B fusion (1)
PD-L1 overexpression + RET-KIF5B fusion + TP53 mutation + AR mutation + RET rearrangement (1)
PD-L1 overexpression + TMB-H (1)
PD-L1 overexpression + TMB-H + ARID1A F2141fs*59 (1)
PD-L1 overexpression + TMB-L (1)
PD-L1 underexpression + EGFR mutation (1)
PD-L1-L (1)
PIK3CA R88Q + PD-L1 expression (1)
POLE mutation + PD-L1 negative + TMB-H (1)
RB1 mutation + PD-L1 expression (1)
RET amplification + TMB-H + PD-L1 expression (1)
ROS1 rearrangement + PD-L1 overexpression (1)
RYR1 mutation + PD-L1 overexpression (1)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression (1)
SQSTM1-NTRK1 + PIK3CA E545K + TP53 L145R + PD-L1 overexpression (1)
STK11 mutation + TMB-H + PD-L1 overexpression (1)
TERT positive + PD-L1 expression (1)
TMB-H + PD-L1 expression + MSI-L/dMMR (1)
TMB-H + RB1 mutation + PD-L1 underexpression (1)
TMB-L + PD-L1 underexpression (1)
TP53 mutation + MET amplification + PD-L1 overexpression (1)
TP53 mutation + PD-L1 expression (1)
TP53 mutation + PD-L1 negative (1)
TP53 mutation + TMB-H + PD-L1 overexpression (1)
TTF1 expression + NAPSA expression + PD-L1 expression + TMB-H (1)
ARID1A mutation + PD-L1 expression (0)
DDX3X mutation + PD-L1 overexpression (0)
LDHA-H + PD-L1 negative (0)
LDHB-H + PD-L1 negative (0)
NOTCH4 mutation + PD-L1 expression + TMB-H (0)
PD-L1 overexpression + BRAF mutation (0)
PD-L1 underexpression + ALK wild-type (0)
PD-L1 underexpression + EGFR wild-type (0)
PD-L1-H (0)
STAT3 mutation + PD-L1 overexpression (0)
›
Associations
(28)
News
Trials
Search handles
@AMansfieldMD
@AndresFCardonaZ
@BenjaminBesseMD
@CharuAggarwalMD
@DrBonillaOnc
@DrSanjayPopat
@DrTylerStewart
@Dr_RShatsky
@FernandoOnco
@FordePatrick
@GeorgeSledge51
@HeadNeckMD
@HenningWillers
@ILSONDavid
@KellyBorgesAra2
@LeciaSequist
@Mat_Guc
@NDeVitoMD
@PatelOncology
@RManochakian
@StephenVLiu
@Tony_Calles
@abhenilmittal
@chulkimMD
@dr_yakupergun
@esinghimd
@n8pennell
@oncologician
@stolaney1
Search handles
@AMansfieldMD
@AndresFCardonaZ
@BenjaminBesseMD
@CharuAggarwalMD
@DrBonillaOnc
@DrSanjayPopat
@DrTylerStewart
@Dr_RShatsky
@FernandoOnco
@FordePatrick
@GeorgeSledge51
@HeadNeckMD
@HenningWillers
@ILSONDavid
@KellyBorgesAra2
@LeciaSequist
@Mat_Guc
@NDeVitoMD
@PatelOncology
@RManochakian
@StephenVLiu
@Tony_Calles
@abhenilmittal
@chulkimMD
@dr_yakupergun
@esinghimd
@n8pennell
@oncologician
@stolaney1
Filter by
Latest
10ms
Encouraging results in non-clear cell RCC. However, efficacy appears to be lower in the chromophobe subtype and in the PDL1-negative group. In the chromophobe type, lenvatinib + everolimus may be more effective. (@dr_yakupergun)
10 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
everolimus • Lenvima (lenvatinib)
11ms
#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick @KatieKeaneMD https://t.co/iRoM58oSHF (@HenningWillers)
11 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
11ms
#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick https://t.co/iRoM58oSHF (@HenningWillers)
11 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
11ms
#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick @KatieKeaneMD @JustinGainor https://t.co/iRoM58oSHF (@HenningWillers)
11 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
11ms
HPV Advances: Dr. @DrJaredWeiss discusses treatment options for patients with head and neck cancer who have a low (below 20) or negative PD-L1. https://t.co/UquZHLFuTO (@cancerGRACE)
11 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
12ms
Some provocative discussions at #RomeLung23 on adjuvant immunotherapy in PDL1 negative NSCLC @FedericoCappuz1 @LuisPaz_Ares @delvysra @EnriquetaFelip @ThomasW35874311 (@StephenVLiu)
12 months ago
Clinical
|
PD-L1 negative
12ms
PDL1 negative #LCSM is a challenger disease. More #clinicaltrials are needed in this setting. In this weekend I talk about therapy available in my country and the gap between public and private care (the dead valley). Beyond later diagnosis, access to new drugs are scarce 🥹 (@FernandoOnco)
12 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
12ms
Dr. @FordePatrick at #RomeLung23 discusses how PDL1 could influence perioperative immunotherapy for NSCLC. Do we need chemo for PDL1 high? (worth studying) Should we give neoadjuvant IO in PDL1 negative cases? (yes if giving chemo) #LCSM (@StephenVLiu)
12 months ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
📊 Pembro for all is the poll favorite Personally, I remain less inclined to offer adjuvant pembro for patients with PDL1 negative disease. #lcsm https://t.co/GhEctGRLK2 (@esinghimd)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Keytruda (pembrolizumab)
over1year
The benefit of pembrolizumab in Pd-l1 negative NSCLC @CharuAggarwalMD @DrSteveMartin @deeptibehl1 https://t.co/E1ewd3WDY1 (@oncologician)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Keytruda (pembrolizumab)
over1year
As presented by Dr. @peters_solange at #ESMO22, adjuvant pembrolizumab had a DFS HR 0.82 in PDL1 high, 0.67 in PDL1 low and 0.78 in PDL1 negative. Different from IMpower 010 where greatest benefit was in PDL1 high subset (DFS HR 0.43), which aligns more to expectations. #LCSM (@StephenVLiu)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 underexpression • PD-L1 negative • PD-1-L • PD-L1-L
|
Keytruda (pembrolizumab)
over1year
Promising approach in upfront PDL-1 negative TNBC. (@abhenilmittal)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Role of IO in LABC ( TNBC ) in PDL 1 negative tumors...? 🙏 (@myfight4cancer)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Avelumab/axitinib in B3 thymoma & thymic carcinoma (CAVEATT) N=32 (thymic carcinoma majority) ORR=34% Similar PFS between between PD-L1 high vs. PD-L1 low/negative is notable Incidence of serious irAEs=12% (similar to PD-1 monoTx) @TheLancetOncol https://t.co/LQL8ueEWJQ (@chulkimMD)
over 1 year ago
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 underexpression • PD-L1 negative
|
Bavencio (avelumab) • Inlyta (axitinib)
over1year
Very clinically helpful and nuanced discussion of management of PDL1 negative lung cancer. I really enjoyed this one. Thank you @HosseinBorghaei @StephenVLiu Dr Reyes Barnabe Caro https://t.co/nRnAg2T9Of (@LeciaSequist)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Fox Chase’s Dr. @HosseinBorghaei joins Dr. Bernabe and host @StephenVLiu for a discussion on the management of metastatic, PDL1 negative NSCLC NSCLC on Lung Cancer Considered. Listen now: https://t.co/BSLMiGG04j @IASLC (@FoxChaseCancer)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
In this virtual tumor board episode of #LungCancerConsidered, the official @IASLC podcast, I discuss management of advanced PD-L1 negative NSCLC with Drs. @HosseinBorghaei and Reyes Bernabe Caro. #LCSM https://t.co/tT8wdXE7A3 (@StephenVLiu)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Host @StephenVLiu leads a discussion on the management of metastatic, PDL1 negative #NSCLC with @HosseinBorghaei, Chief of Thoracic Oncology at @FoxChaseCancer, & Dr. Reyes Bernabe Caro, Section Chief of Medical Oncology at @UGTHUVRocio. Listen Now: https://t.co/aV6zfCYkzV #LCSM (@IASLC)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Tune in next week for a virtual tumor board on #LungCancerConsidered, the official @IASLC podcast, where I discuss management of advanced PDL1 negative NSCLC with Drs. Reyes Bernabe Caro and @HosseinBorghaei. #LCSM https://t.co/Uyom7qDQWF (@StephenVLiu)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over1year
Agree. Benefit in PD-L1+ is mainly driven by PD-L1>50% subgroup (again with caution as this is a no formal stat test at an IA in a subgroup). Impactful to me to see that atezolizumab could be even harmful in PD-L1 negative. #WCLC22 #lcsm (@Tony_Calles)
over 1 year ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Tecentriq (atezolizumab)
over1year
Interim OS analysis of IMpower010, adjuvant Atezolizumab in resected NSCLC presented at #WCLC2022 👉 no significant OS difference 👉 trend to improved OS in PD-L1 pos, especially in min 50% 👉 no signal for benefit in PD-L1 negative patients (@Mat_Guc)
over 1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Tecentriq (atezolizumab)
over1year
PDL1 expression and #mesothelioma: hot topic. Both @IbiayiMD and @AMansfieldMD (joining remotely) agree that PDL1 status is not currently predictive of IO benefit and PDL1 negative tumors should still receive IO. Agree fully: evidence based conclusion. #WCLC22 (@DrSanjayPopat)
over 1 year ago
IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
almost2years
Hi there, is there any immunotherapy for HER2 negative breast cancer , PDL1 is Negative, what is the best treatment, my wife is very sick. (@AVESHT1)
almost 2 years ago
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 negative • PD-L1 negative
almost2years
#ASCO22 Abstract #9003 looks intriguing. Eftilagimod alpha (soluble LAG-3 protein, subQ) plus pembro for 1L NSCLC showed RR 37% including 55% in PDL1 high and 27% in PDL1 negative NSCLC. Hope to see data on durability in oral presentation to be given by Dr. @EnriquetaFelip. #LCSM (@StephenVLiu)
almost 2 years ago
PD-L1 (Programmed death ligand 1) • LAG3 (Lymphocyte Activating 3)
|
PD-L1 negative
|
Keytruda (pembrolizumab) • ImmuFact (eftilagimod alpha)
2years
I really agree w/you: CPS<5👉+ IO just for ⬆️ORR! Although, we recently discussed a rare case of gastric cancer with CNS metastasis + PDL-1 negative (& good PS)😊Despite the neg PDL-1, we suggest chemo+IO based on this interesting Korean case report: https://t.co/CoBmKJW5jd (@KellyBorgesAra2)
2 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
2years
While all still reviewing/processing exciting data, in my first look, not sure patients with negative PDL-1 #NSCLC are benefiting much (similar to what we saw in adjuvant atezo data) (@RManochakian)
2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Tecentriq (atezolizumab)
2years
51 years old, female, uT2N0m0 stomach cancer 1.5cm. MSS, her2 negative, PDL1 CPS-3. Perioperative CT - four cycles of FLOT. Gastrectomy - 0.3 cm residual disease, ypT1b, 41 lymph nodes negatives. What would you recomend ? @YJanjigianMD @duiliorocha_onc @AnelisaCoutinh1 Tks. (@pam65230529)
2 years ago
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 negative • PD-L1 negative
2years
But still, based on PACIFIC, we would expect a benefit of consolidation IO in this setting even for patients with PDL1 negative status #LCSM (@CharuAggarwalMD)
2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
2years
Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)
2 years ago
Clinical
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • ALK negative
2years
What is your first line treatment option for metastatic fibrolamellar HCC? Child-Pugh A5. Molecular profiling showed MSS, negative PD-L1 and low TMB at 2. No NTRK fusion. DNAJB1 pathogenic fusion and TERT promoter pathogenic variant @GABOUALFA @GIcancerDoc @pashtoonkasi (@m_khushman)
2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • NTRK (Neurotrophic receptor tyrosine kinase) • DNAJB1 (DnaJ Heat Shock Protein Family (Hsp40) Member B1)
|
PD-L1 negative • TMB-L • PD-L1 negative + TMB-L • NTRK fusion
over2years
#SABCS2021 Nimbus results: 30 pts accrued, 21 HR+ and 9 TNBC. Most were PD-L1 negative, and median TMB was 10.9. 5 patients had confirmed response and 6 SD. CBR was seen in 5 pts. 3/5 responders were ER pos and only 1 was PD-L1 pos. TMB >/= 14 in 3/5 responders. MDR 12.1 mo. (@GeorgeSledge51)
over 2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over2years
It can be approved by private insurers after a peer to peer. For Medicare, it is listed in the NCCN guidelines for PDL1 negative, driver negative NSCLC as a Category 2A. Not positive about the current policy of CMS on NCCN 2A recs. (@StephenVLiu)
over 2 years ago
NCCN guideline • Reimbursement • Medicare • CMS
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over2years
4 year OS of 24% in PDL1 negative patients is amazing, is there no plan to prove this in a trial the FDA would accept? Right now we can't use this combo in that population, or am I wrong, is anyone using (and getting coverage) for off-label nivo/ipi in PDL1 <1%? #LCSM (@n8pennell)
over 2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
over2years
#ESMO21 Median time to initiation of durvalumab was 56 days (which is quite real-world). Median duration of therapy was 11 months (of the planned 12 months). 73% were PDL1 positive, 18% PDL1 negative but PDL1 not tested for 432 patients. #LCSM @myESMO (@StephenVLiu)
over 2 years ago
Clinical • Real-world evidence
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Imfinzi (durvalumab)
over2years
#ESMO21 mPFS by subgroup including PDL1 with mPFS in PDL1 positive of 22.4m and PDL1 negative of 16.3m. Outcomes better for non-squamous, as expected. Also included pts receiving sequential chemoradiation and mPFS of 19.4m encouraging. Helpful data here. #LCSM @myESMO (@StephenVLiu)
over 2 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
over2years
.@JulieBrahmer offers a really nice perspective on use of IO in 1L mNSCLC ✴️ D+CT not better for OS ✴️ D+T+CT improves PFS, OS c/w CT ✴️Probably relevant in PDL1 negative population #LCSM #WCLC21 @IASLC (@CharuAggarwalMD)
over 2 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
over2years
Do you have any research por TNBC with negative PDL1 biomarkers? (@VERONICABASA)
over 2 years ago
IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
almost3years
What is the real impact of immunotolerance in patients with NSCLC and intermediate or negative PDL1 exposed to regimens such as 9LA, 227 or Poseidon? (@AndresFCardonaZ)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
almost3years
#ASCO21 Looking at subgroups of the all-randomized stage II-IIIA dataset, we see greater DFS benefit for PDL1 high (TC, SP263) with HR 0.43 compared to 0.66 for PDL1 positive and 0.97 for PDL1 negative. What we need to see is PDL1 low (1-49%). #LCSM (@StephenVLiu)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 underexpression • PD-L1 negative • PD-1-L
|
VENTANA PD-L1 (SP263) Assay
almost3years
#ASCO21 The benefit for OS, PFS and DOR was seen across all PDL1 strata (PDL1 negative, positive and high), consistent with chemo/IO approaches in other studies. Again, no maintenance chemotherapy here so important to follow up as done here. #LCSM (@StephenVLiu)
almost 3 years ago
Clinical
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
almost3years
#ASCO21 Breakdown of PACIFIC by PDL1 status. Notable fraction of patients unknown PDL1 and the positive vs negative comparison was not predefined. But in that post-hoc analysis, PDL1 negative cohort did not fare as well with durvalumab. PDL1 part of EMA label, not US label. #LCSM (@StephenVLiu)
almost 3 years ago
Clinical • Retrospective data
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Imfinzi (durvalumab)
almost3years
#MedTwitter #pcsm #PancreaticCancer colleagues: Any active trials or ideas based on these genomics 🧬 pMMR, TMB 3 Mut/Mb and PD-L1 negative; exhausted all SoC but exceptional responder since diagnosis in 2016 @EileenMOReilly @Dr_R_Kurzrock @ShaalanBeg @MPishvaian @VivekSubbiah (@DrBonillaOnc)
almost 3 years ago
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login